Self-immolative polymer-based immunogenic cell death inducer for regulation of redox homeostasis. (April 2023)

• Record Type: Journal Article
• Authors: Jeon, Jueun; Yoon, Been; Dey, Anup; Song, Seok Ho; Li, Yuce; Joo, Hyeyeon; Park, Jae Hyung
• Is Part Of: Biomaterials. Volume 295(2023)
• Publication Date: 2023-04
• Subjects: Self-immolative polymer -- Oxidative stress -- Endoplasmic reticulum stress -- Immunogenic cell death -- Cancer immunotherapy; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2023.122064
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Doxorubicin (DOX), widely used as an anticancer drug, is considered an immunogenic cell death (ICD) inducer that enhances cancer immunotherapy. However, its extended application as an ICD inducer has been limited owing to poor antigenicity and inefficient adjuvanticity. To enhance the immunogenicity of DOX, we prepare a reactive oxygen species (ROS)-responsive self-immolative polymer (R–SIP) that can efficiently destroy redox homeostasis via self-immolation-mediated glutathione depletion in cancer cells. Owing to its amphiphilic nature, R–SIP self-assemble into nano-sized particles under aqueous conditions, and DOX is efficiently encapsulated inside the nanoparticles by a simple dialysis method. Interestingly, when treated with 4T1 cancer cells, DOX-encapsulated R–SIP (DR-SIP) induces the phosphorylation of eukaryotic translation initiation factor 2α and overexpression of ecto-calreticulin, resulting in endoplasmic reticulum-associated ICD. In addition, DR-SIP contributes to the maturation of dendritic cells by promoting the release of damage-associated molecular patterns (DAMPs) from cancer cells. When intravenously administered to tumor-bearing mice, DR-SIP remarkably inhibits tumor growth compared with DOX alone. Overall, DR-SIP may have the potential to elicit an immune response as an ICD inducer.